Amedisys Stock Forecast, Price & News

Amedisys (NASDAQ:AMED) Frequently Asked Questions

Is Amedisys a buy right now?

14 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Amedisys in the last year. There are currently 1 sell rating, 5 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Amedisys stock.
View analyst ratings for Amedisys or view top-rated stocks.

How has Amedisys' stock been impacted by Coronavirus?

Amedisys' stock was trading at $170.47 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, AMED stock has decreased by 17.4% and is now trading at $140.74.
View which stocks have been most impacted by COVID-19.

Are investors shorting Amedisys?

Amedisys saw a increase in short interest in the month of October. As of October 15th, there was short interest totaling 877,400 shares, an increase of 26.4% from the September 30th total of 693,900 shares. Based on an average daily trading volume, of 404,400 shares, the days-to-cover ratio is currently 2.2 days. Currently, 2.7% of the shares of the company are short sold.
View Amedisys' Short Interest.

When is Amedisys' next earnings date?

Amedisys is scheduled to release its next quarterly earnings announcement on Wednesday, February 23rd 2022.
View our earnings forecast for Amedisys.

How were Amedisys' earnings last quarter?

Amedisys, Inc. (NASDAQ:AMED) posted its quarterly earnings results on Tuesday, November, 2nd. The health services provider reported $1.53 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $1.37 by $0.16. The health services provider had revenue of $553.49 million for the quarter, compared to analyst estimates of $568.55 million. Amedisys had a trailing twelve-month return on equity of 24.15% and a net margin of 9.98%. During the same quarter in the prior year, the business earned $2.24 EPS.
View Amedisys' earnings history.

How will Amedisys' stock buyback program work?

Amedisys announced that its Board of Directors has approved a share buyback program on Wednesday, August 4th 2021, which allows the company to repurchase $100,000,000.00 in shares, according to EventVestor. This repurchase authorization allows the company to repurchase up to 1.2% of its shares through open market purchases. Shares repurchase programs are often a sign that the company's board of directors believes its shares are undervalued.

What guidance has Amedisys issued on next quarter's earnings?

Amedisys updated its FY 2021 earnings guidance on Tuesday, November, 9th. The company provided earnings per share (EPS) guidance of $5.880-$5.930 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $6.080. The company issued revenue guidance of $2.20 billion-$2.21 billion, compared to the consensus revenue estimate of $2.25 billion.

What price target have analysts set for AMED?

14 analysts have issued 12-month price objectives for Amedisys' shares. Their forecasts range from $150.00 to $235.00. On average, they expect Amedisys' stock price to reach $203.71 in the next twelve months. This suggests a possible upside of 44.7% from the stock's current price.
View analysts' price targets for Amedisys or view top-rated stocks among Wall Street analysts.

Who are Amedisys' key executives?

Amedisys' management team includes the following people:

• Paul B. K. Kusserow, Chairman & Chief Executive Officer
• Christopher T. Gerard, President & Chief Operating Officer (LinkedIn Profile)
• Scott G. Ginn, Chief Financial Officer & Executive Vice President (LinkedIn Profile)
• Michael P. North, Chief Information Officer (LinkedIn Profile)
• Denise M. Bohnert, Chief Compliance Officer

What is Paul B. Kusserow's approval rating as Amedisys' CEO?

297 employees have rated Amedisys CEO Paul B. Kusserow on Glassdoor.com. Paul B. Kusserow has an approval rating of 79% among Amedisys' employees.

Who are some of Amedisys' key competitors?

Some companies that are related to Amedisys include Laboratory Co. of America (LH), Quest Diagnostics (DGX), DaVita (DVA), Chemed (CHE), R1 RCM (RCM), AMN Healthcare Services (AMN), LHC Group (LHCG), CorVel (CRVL), MEDNAX (MD), Tivity Health (TVTY) and Cross Country Healthcare (CCRN).
View all of AMED's competitors.

What other stocks do shareholders of Amedisys own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amedisys investors own include NVIDIA (NVDA), Alibaba Group (BABA), Johnson & Johnson (JNJ), Pfizer (PFE), Adobe (ADBE), Intel (INTC), QUALCOMM (QCOM), Broadcom (AVGO), Cisco Systems (CSCO) and Home Depot (HD).

What is Amedisys' stock symbol?

Amedisys trades on the NASDAQ under the ticker symbol "AMED."

Who are Amedisys' major shareholders?

Amedisys' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (11.89%), William Blair Investment Management LLC (2.34%), Wellington Management Group LLP (2.13%), Credit Suisse AG (1.42%), Invesco Ltd. (1.32%) and Geode Capital Management LLC (1.30%). Company insiders that own Amedisys stock include Bruce D Perkins, Bruce D Perkins, Christopher Gerard, David L Kemmerly, Denise M Bohnert, Jake L Netterville, Jeffrey A Rideout, Julie D Klapstein, Michael Paul North, Scott G Ginn, Sharon Brunecz, Teresa L Kline and Vickie L Capps.
View institutional ownership trends for Amedisys.

Which institutional investors are selling Amedisys stock?

AMED stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Invesco Ltd., Thrivent Financial for Lutherans, Fuller & Thaler Asset Management Inc., AXA S.A., Alliancebernstein L.P., Allianz Asset Management GmbH, and BlackRock Inc.. Company insiders that have sold Amedisys company stock in the last year include Bruce D Perkins, Christopher Gerard, David L Kemmerly, Denise M Bohnert, Michael Paul North, and Scott G Ginn.
View insider buying and selling activity for Amedisys or view top insider-selling stocks.

Which institutional investors are buying Amedisys stock?

AMED stock was bought by a variety of institutional investors in the last quarter, including Capital Research Global Investors, Credit Suisse AG, Bellevue Group AG, Polar Capital Holdings Plc, Voloridge Investment Management LLC, NFJ Investment Group LLC, Ensign Peak Advisors Inc, and Dimensional Fund Advisors LP. Company insiders that have bought Amedisys stock in the last two years include Bruce D Perkins, Teresa L Kline, and Vickie L Capps.
View insider buying and selling activity for Amedisys or or view top insider-buying stocks.

How do I buy shares of Amedisys?

Shares of AMED can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Amedisys' stock price today?

One share of AMED stock can currently be purchased for approximately $140.74.

How much money does Amedisys make?

Amedisys has a market capitalization of $4.59 billion and generates $2.07 billion in revenue each year. The health services provider earns $183.61 million in net income (profit) each year or $6.66 on an earnings per share basis.

How many employees does Amedisys have?

Amedisys employs 21,000 workers across the globe.

When was Amedisys founded?

Amedisys was founded in 1982.

What is Amedisys' official website?

The official website for Amedisys is www.amedisys.com.

Where are Amedisys' headquarters?

Amedisys is headquartered at 3854 AMERICAN WAY SUITE A, BATON ROUGE LA, 70816.

How can I contact Amedisys?

Amedisys' mailing address is 3854 AMERICAN WAY SUITE A, BATON ROUGE LA, 70816. The health services provider can be reached via phone at (225) 292-2031, via email at [email protected], or via fax at 225-292-8163.